Anti-HER2 therapy demonstrates limited efficacy and lacks robust evidence in metastatic prostate cancer, primarily due to inconsistent outcomes and inadequate clinical responses (19, 20). This evidence concerns the gene ERBB2 and metastatic prostate carcinoma.